Method for reducing the weight of a subject or inhibiting weight gain in a subject

• US 8,242,171 B2
• Filed: 01/07/2010
• Issued: 08/14/2012
• Est. Priority Date: 12/29/2003
• Status: Active Grant

• Current Assignee: President and Fellows of Harvard College (Harvard Corporation), The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation), The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Sinclair, David A., Alexander-Bridges, Maria
• Primary Examiner(s): Weddington, Kevin E
• Application Number:
  US12/683,998
• Publication Number:
  US 20100316679A1
• Time in Patent Office: 950 Days
• Field of Search: 514/546, 514/909, 424/725, 424/776
• US Class Current: 514/546
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin

Abstract

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.

Claims

1. A method for reducing the weight of a subject, or inhibiting weight gain in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition consisting essentially of resveratrol.

2. The method of claim 1, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable carriers.

3. The method of claim 2, wherein the one or more pharmaceutically acceptable carriers is/are one or more liquid or solid fillers, diluents, excipients, solvents or encapsulating materials selected from the group consisting of:

sugars, optionally lactose, glucose and/or sucrose;

starches, optionally corn starch and/or potato starch;

cellulose, and its derivatives, optionally sodium carboxymethyl cellulose, ethyl cellulose and/or cellulose acetate;

powdered tragacanth;

malt;

gelatin;

talc;

excipients, optionally cocoa butter and/or suppository waxes;

oils, optionally peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and/or soybean oil;

glycols, optionally propylene glycol;

polyols, optionally glycerin, sorbitol, mannitol and/or polyethylene glycol;

esters, optionally ethyl oleate and/or ethyl laurate;

agar;

buffering agents, optionally magnesium hydroxide and/or aluminum hydroxide;

alginic acid;

pyrogen-free water;

isotonic saline;

Ringer'"'"'s solution; and

phosphate buffer solutions.

4. The method of claim 1, wherein the resveratrol is not in a form that is naturally-occurring.